NCT03727555View on ClinicalTrials.gov

IT and IV Lentiviral Gene Therapy for X-ALD

NARecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
X-linked Adrenoleukodystrophy
Interventions
GENETIC

Intrathecal and intravenous LV gene therapy

Direct IT and IV LV gene therapy to deliver high levels of LVs at 1-2×10\^9 multiplicity of infection/ml which carry normal ABCD1 gene

Trial Locations (1)

518000

RECRUITING

Shenzhen Geno-immune Medical Institute, Shenzhen

All Listed Sponsors
lead

Shenzhen Geno-Immune Medical Institute

OTHER

NCT03727555 - IT and IV Lentiviral Gene Therapy for X-ALD | Biotech Hunter | Biotech Hunter